Dr.Zhao and his team published four-year follow-up studies demonstrated the long-term safety and clinical efficacy of Stem Cell Educator therapy for the treatment of type 1 diabetes (T1D) and T2D.

Clinical data revealed the long-lasting therapeutic efficacy of Stem Cell Educator (SCE) therapy in T1D and T2D subjects after receiving one treatment with SCE therapy.  Specifically, recent onset T1D patients could achieve normal fasting C-peptide levels and remain completely recovered with no relapse after 4 years. To our knowledge, this is the first long-term clinical study demonstrated that islet β cell function has been completely and safely rescued in these recent onset T1D subjects after controlling the autoimmunity by the SCE therapy. Read more in the article at the STEM CELLS Translational Medicine.